The NEFH Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the NEFH gene in the Raji B lymphoblastoid cell line. This product serves as a loss-of-function model for investigating neurofilament heavy chain biology and for validating NEFH-targeted reagents. As a polyclonal population, the cells exhibit heterogeneous gene-editing outcomes across the pool, providing a robust system for experiments that do not require clonal homogeneity. The knockout model enables functional dissection of NEFH-mediated cytoskeletal organization and signaling in a non-neuronal background.
The Raji host cell line is an immortalized human B lymphocyte derived from a Burkitt lymphoma, and it is Epstein-Barr virus (EBV) positive. This cell line is extensively utilized in immunological and cancer research due to its stable proliferation and well-characterized signaling pathways. Importantly, Raji cells do not endogenously express neurofilament proteins, including NEFH, NEFL, and NEFM, which makes them an ideal null background for studying ectopic NEFH expression and for antibody specificity testing. The loss of endogenous neurofilament eliminates confounding signals in downstream assays.
NEFH encodes the neurofilament heavy chain, a type IV intermediate filament protein that forms heteropolymers with NEFL and NEFM to provide structural support and regulate axon caliber in neurons. The protein is extensively phosphorylated by kinases including CDK5, GSK3B, MAPK1/ERK2, MAPK3/ERK1, and p38 MAPK, which modulate its assembly and interactions. NEFH acts downstream of these kinases and influences cytoskeletal dynamics through interactions with tubulin, actin, and MAPT/Tau. Additionally, NEFH associates with molecular chaperones like HSPA8 and the dynein activator DCTN1, linking it to axonal transport. Disruption of NEFH in this model eliminates these interactions, enabling precise analysis of NEFH-dependent mechanisms.
In the Raji cellular context, knockout of NEFH provides a clean genetic background to explore neurofilament protein function without endogenous compensation. This model is particularly valuable for studying ectopically expressed wild-type or mutant NEFH constructs, enabling structure-function analyses, post-translational modification studies, and protein interaction mapping by techniques such as co-immunoprecipitation. Since Raji cells lack neuronal-specific scaffolds, the system permits focused investigation of NEFH interactions with signaling molecules like CDK5 and GSK3B, independent of neuronal context. Thus, it serves as a versatile platform for mechanistic studies relevant to neurodegenerative diseases including amyotrophic lateral sclerosis, Charcot-Marie-Tooth disease, and Parkinson’s disease.
Typical applications of NEFH Knockout Raji Polyclonal Cells include use as negative controls for NEFH antibody validation in Western blotting, immunofluorescence, and flow cytometry. The cells are suitable for ectopic expression experiments with RT-qPCR and sequencing confirmation. Protein interaction studies by co-immunoprecipitation and phospho-signaling analysis of MAPK pathway components benefit from the null background. This model also supports therapeutic target validation and drug screening in a non-neuronal context. For further information, please contact Ascent Research.
